Coronado Industries Corrects Press Release Issued Earlier Today.Business/Technology Editors FOUNTAIN HILLS, Az.--(BUSINESS WIRE)--Feb. 5, 2001 Coronado Industries, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CDIK), a manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma, wishes to correct information contained in a press release issued earlier today. Contrary to the headline of the earlier release, clinical trials to be conducted in Italy of the Company's PNT PNT Point PNT Paint (MacPaint graphic file format) PNT Patient PNT Pentagon (Washington, DC; US DoD) PNT Positioning, Navigation and Timing PNT Prime Number Theorem PNT Phenytoin (TM) treatment for glaucoma have not been postponed. A trip to Italy by the Company's Medical Director, Dr. Leo Leo, in astronomy Leo [Lat.,=the lion], northern constellation lying S of Ursa Major and on the ecliptic (apparent path of the sun through the heavens) between Cancer and Virgo; it is one of the constellations of the zodiac. Bores, has been temporarily postponed until after his trip mid-February to Kenya. Coronado Industries, through its wholly-owned subsidiaries American Glaucoma and Ophthalmic International, focuses on the development and testing of a patented procedure, Pneumatic Trabeculoplasty (PNT(TM)), a non-invasive, highly effective, and low-cost alternative to traditional treatments. Currently, the Company is allowed to market its pneumatic suction device and treatment throughout the European marketplace under a CE Mark (allowing manufacturers to freely sell their products) from the European Commission. Pending FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval, the Company will license its patented treatment procedure and equipment in the United States. For additional information, see www.coronadoindustries.com or www.otcfn.com/cdik/4pg.html Forward-looking statements in this release are made pursuant to the "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion